RDHL | tickerfilter.com

Fundamental analysis

15%

Profitability 15%

Dept financing 13%

Liquidity 75%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.76%

1 Month

-12.14%

3 Months

-25.81%

6 Months

-37.03%

1 Year

-60.47%

2 Year

-99.08%

Key data

Stock price

$8.52

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$6.43 - $82.00

52 WEEK CHANGE

-$0.61

MARKET CAP

10.835 M

YIELD

N/A

SHARES OUTSTANDING

1.275 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$192,926

AVERAGE 30 VOLUME

$247,738

Company detail

CEO: Dror Ben-Asher
Region: US
Website: https://www.redhillbio.com/
Employees: 150
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

redhill biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. redhill has an experienced management team, board of directors and advisory board based in israel, the us, canada and europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise

RDHL - Redhill Biopharma Ltd. - ADR